Full-Time

Thought Leader Liaison

Northeast

Updated on 7/23/2026

Dyne Therapeutics

Dyne Therapeutics

201-500 employees

Develops muscle-disease therapies using FORCE platform

Compensation Overview

$230k - $260k/yr

United States

In Person

Residency within assigned Northeast region; within driving distance of a major airport; domestic travel up to 80%.

Category
Medical, Clinical & Veterinary (1)
Required Skills
Data Analysis

Get referred to Dyne Therapeutics

Find people who can refer or advise you

Requirements
  • Bachelor’s degree required; advanced degree preferred.
  • 10+ years of experience in biotechnology or pharmaceutical commercial roles, with experience in rare disease or specialty markets strongly preferred.
  • Demonstrated experience engaging neuromuscular or rare disease thought leaders in a commercial context.
  • Strong understanding of the rare disease commercialization landscape, including diagnosis complexity, referral dynamics, and patient advocacy.
  • Proven ability to translate complex scientific and clinical insights into clear, innovative, and actionable commercial strategies. Self-starter with the ability to deliver results in therapeutic areas with high unmet need.
  • Excellent interpersonal, oral, and written communication skills, with strong execution focus and executive presence, and the ability to influence without authority.
  • Strong cross-functional collaboration skills and experience operating in matrixed organizations.
  • Demonstrated commitment to ethical, compliant engagement practices.
  • Proven ability to manage a large geographical territory.
  • Domestic travel up to 80% is required.
Responsibilities
  • Develops and executes a comprehensive thought leader engagement strategy focused on rare neuromuscular diseases, aligned with Dyne’s commercial and portfolio priorities.
  • Identifies, profiles, and prioritizes national and regional neuromuscular thought leaders based on expertise, influence, and strategic relevance.
  • Builds and sustains long-term, trust-based relationships with clinicians and experts treating rare neuromuscular disorders through compliant, value-driven engagement.
  • Serves as a credible commercial partner in discussions related to disease state education, evolving treatment paradigms, and unmet needs in neuromuscular disease.
  • Captures, synthesizes, and translates insights from neuromuscular thought leaders into actionable recommendations for brand, launch, and lifecycle strategy.
  • Provides strategic input into positioning, messaging, and tactical planning that reflects the unique dynamics of rare disease diagnosis, treatment, and patient journeys.
  • Monitors KOL insights related to current and future market dynamics and competitive intelligence through customer meetings, congresses, advisory boards, and analytics.
  • Shares insights with commercial leadership and cross-functional partners to inform decision-making and optimize execution.
  • Leads commercial engagement strategy for key neuromuscular congresses, including pre-, during-, and post-meeting planning and follow-up.
  • Designs and executes advisory boards, speaker programs, and peer-to-peer educational initiatives focused on rare neuromuscular disease education.
  • Identifies and recruits appropriate KOLs for content development and other marketing projects, such as web content, training, handouts, and related materials.
  • Partners cross-functionally to ensure consistency, effectiveness, and compliance across engagement forums.
  • Collaborates and interfaces regularly across regions and with multiple departments, including Sales, Marketing, Medical Affairs, Market Access, Training, Legal, and Compliance, to ensure aligned and compliant execution.
  • Manages vendor partnerships as needed, including medical education agencies, meeting services providers, and other external partners.
  • Establishes metrics to assess effectiveness, impact, and ROI of thought leader engagement activities.
  • Ensures all interactions adhere to regulatory, legal, and company compliance standards.

Dyne Therapeutics develops therapies for serious muscle diseases using its FORCE™ platform, which helps deliver oligonucleotide medicines to muscle tissue. Through a portfolio of experimental therapies, the company advances them in clinical trials (ACHIEVE and DELIVER) with the aim of treating rare muscle diseases. The product works by enhancing targeted delivery of oligonucleotides to muscle, enabling existing genetic medicines to reach affected tissues more effectively. Dyne differentiates itself by its proprietary FORCE™ technology and its focus on rare muscle diseases, positioning itself for growth as trials progress toward potential commercialization. The company’s goal is to bring effective treatments to patients and families affected by serious muscle diseases, expanding options as its therapies advance through development and, potentially, regulatory approval.

Company Size

201-500

Company Stage

IPO

Headquarters

Waltham, Massachusetts

Founded

2017

Get referred to Dyne Therapeutics

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Preclinical data shows sustained dystrophin expression and muscle function improvement after single low dose[1].
  • ACHIEVE trial shows dose-dependent splicing correction and functional improvement in DM1 patients[3].
  • Dyne secured $400M debt facility to support US launches of DMD and DM1 therapies within two years[3]

What critics are saying

  • Sarepta's upadacersen dominates DMD market with 80% adoption, blocking Dyne's switch opportunities in 12–18 months
  • FDA rejection risk for accelerated approval due to inadequate Phase 1/2 data persists in 6–12 months
  • Dyne faces insolvency within 12 months if FDA denies approval due to $200M debt and equity dilution

What makes Dyne Therapeutics unique

  • Dyne's FORCE™ platform targets TfR-1 for precise oligonucleotide delivery to muscle and CNS[1][2].
  • Dyne pioneers low-dose, infrequent therapy for DM1 using FORCE™ platform validation[4][6].
  • Dyne advances clinical programs for DMD and DM1 with fast track and orphan drug designations[3].

Help us improve and share your feedback! Did you find this helpful?

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

0%

2 year growth

-3%
Dyne Therapeutics
Dec 10th, 2025
Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock | Dyne Therapeutics, Inc.

(Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the pricing of an upsized underwritten public offering of 18,980,478 shares of its common stock at a public offering price of $18.44 per share.